Patents Represented by Attorney Robert A. Conrad
  • Patent number: 5416211
    Abstract: Processes for preparing 5-substituted pyrrolo[2,3-d]pyrimidines which are useful as intermediates for the preparation of pyrrolo[2,3-d]pyrimidine antineoplastic agents or as antineoplastic agents themselves are provided.
    Type: Grant
    Filed: May 24, 1993
    Date of Patent: May 16, 1995
    Assignee: Eli Lilly and Company
    Inventors: Charles J. Barnett, Thomas M. Wilson
  • Patent number: 5401861
    Abstract: A stereoselective process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates by contacting a lactol with an amine base in an inert solvent, adjusting the temperature and adding a sulfonating reagent.
    Type: Grant
    Filed: June 22, 1992
    Date of Patent: March 28, 1995
    Assignee: Eli Lilly and Company
    Inventor: Ta-Sen Chou
  • Patent number: 5401838
    Abstract: A stereoselective fusion glycosylation process for prearing beta-anomer enriched 2'-deoxy-2',2'-difluoronucleotides and 2'-deoxy-2'-fluoronucleosides by reacting an alpha-anomer enriched 2-deoxy-2,2-difluorocarbohydrate or 2-deoxy-2-fluorcarbohydrate with at least a 3 molar equivalent of a nucleobase derivative at a temperature sufficient to melt the carbohydrate and nucleobase derivative.
    Type: Grant
    Filed: April 7, 1993
    Date of Patent: March 28, 1995
    Assignee: Eli Lilly and Company
    Inventor: Ta-Sen Chou
  • Patent number: 5364863
    Abstract: This invention provides bicyclic carboxylic esters and amides, their pharmaceutical formulations, and a method for their use in treating migraine, emesis, gastrointestinal disorders, schizophrenia, or anxiety in mammals.
    Type: Grant
    Filed: April 26, 1993
    Date of Patent: November 15, 1994
    Assignee: Eli Lilly and Company
    Inventors: Marlene L. Cohen, William B. Lacefield, David W. Robertson
  • Patent number: 5312936
    Abstract: This invention provides novel phenyl and heterocyclic derivatives, their pharmaceutical formulations and their use for antagonizing angiotensin II receptors in mammals.
    Type: Grant
    Filed: September 17, 1991
    Date of Patent: May 17, 1994
    Assignee: Eli Lilly and Company
    Inventors: Sherryl L. Lifer, Winston S. Marshall, Fariborz Mohamadi, Jon K. Reel, Richard L. Simon, Mitchell I. Steinberg, Celia A. Whitesitt
  • Patent number: 5272253
    Abstract: Targeted drug conjugates which enable a large number of molecules of drug to be directed to a cell by a single molecule of antibody are provided. The invention also provides intermediates for the synthesis of such conjugates and cytotoxic drugs modified in accordance with the cluster concept of the invention.
    Type: Grant
    Filed: July 1, 1991
    Date of Patent: December 21, 1993
    Assignee: Eli Lilly and Company
    Inventors: Gary A. Koppel, Robin E. Offord, Keith Rose, William L. Scott
  • Patent number: 5264445
    Abstract: This compound provides the compound (-)-N"-cyano-N-3-pyridyl-N'-1,2,2-trimethylpropylguanidine, its salts and pharmaceutical formulations, and its method of use for opening potassium channels in mammals.
    Type: Grant
    Filed: October 29, 1992
    Date of Patent: November 23, 1993
    Assignee: Eli Lilly and Company
    Inventors: David W. Robertson, Mitchell I. Steinberg
  • Patent number: 5250572
    Abstract: The present invention provides (R)-norfluoxetine and pharmaceutically acceptable salts thereof capable of selectively occupying 5HT.sub.1c receptors.
    Type: Grant
    Filed: April 21, 1992
    Date of Patent: October 5, 1993
    Assignee: Eli Lilly and Company
    Inventors: David W. Robertson, David T. Wong
  • Patent number: 5250571
    Abstract: The present invention provides (S)-norfluoxetine and pharmaceutically acceptable salts thereof capable of inhibiting the uptake of serotonin.
    Type: Grant
    Filed: April 21, 1992
    Date of Patent: October 5, 1993
    Assignee: Eli Lilly and Company
    Inventors: Ray W. Fuller, David Mitchell, David W. Robertson, Gregory A. Stephenson, David T. Wong
  • Patent number: 5248691
    Abstract: This invention provides novel furanoindoline compounds effective in inhibiting the growth of solid tumors.
    Type: Grant
    Filed: September 3, 1992
    Date of Patent: September 28, 1993
    Assignee: Eli Lilly and Company
    Inventor: Fariborz Mohamadi
  • Patent number: 5243053
    Abstract: This invention provides new stabilized methylene Meldrum's acid precursors, a process for their preparation, and a process for using such compounds in the preparation of methylene Meldrum's acid.
    Type: Grant
    Filed: February 26, 1992
    Date of Patent: September 7, 1993
    Assignee: Eli Lilly and Company
    Inventor: Mohammad Zia-Ebrahimi
  • Patent number: 5238959
    Abstract: The present invention provides 3-(4-substitutedphenoxy)-3-phenyl propanamines capable of inhibiting the uptake of serotonin. These compounds are useful for treating many pharmacological disorders, including depression and obesity. These compounds can also be used to reduce the desire to smoke and consume alcohol.
    Type: Grant
    Filed: April 20, 1992
    Date of Patent: August 24, 1993
    Assignee: Eli Lilly and Company
    Inventors: David W. Robertson, David T. Wong
  • Patent number: 5235064
    Abstract: This invention provides benzene derivatives which are leukotriene antagonists, formulations of those derivatives, intermediates for preparing the derivatives, and a method of using those derivatives for the treatment of conditions characterized by an excessive release of leukotrienes.
    Type: Grant
    Filed: July 27, 1992
    Date of Patent: August 10, 1993
    Assignee: Eli Lilly and Company
    Inventor: D. Mark Gapinski
  • Patent number: 5198360
    Abstract: The present invention comprises an .about.0.8 kb Sac II restriction fragment of phage FP43, which confers the pin phenotype. The present invention allows transduction at high m.o.i. using the phage FP43 high frequency transduction system.
    Type: Grant
    Filed: January 19, 1990
    Date of Patent: March 30, 1993
    Assignee: Eli Lilly and Company
    Inventors: Margaret M. Ballou, Richard H. Baltz, Margaret A. McHenney
  • Patent number: 5196524
    Abstract: Novel fusion reporter genes, fusion reporter proteins, and an improved reporter system for measuring the relative activity of a promoter sequence. A luxAB fusion gene of the present invention is particularly useful as a reporter gene and is derived from the fusion of a luxA gene and a luxB gene from Vibrio harveyi. The gene products of the luxA and luxB genes are the .alpha.- and .beta.-subunits, respectively, of a bacterial luciferase. A fusion protein encoded by a luxAB fusion gene is a single active protein and is particularly useful as a reporter protein having luciferase activity. An advantage of such a reporter system to assay gene expression in many cells which contain FMNH.sub.2, such as bacterial and yeast cells, is that an immediate and quantitative assessment of gene expression may be made from real-time light measurements using intact cells.
    Type: Grant
    Filed: January 6, 1989
    Date of Patent: March 23, 1993
    Assignee: Eli Lilly and Company
    Inventors: Gary D. Gustafson, Thomas D. Ingolia, Gretchen Kirchner, Jean L. Roberts
  • Patent number: 5171882
    Abstract: This invention provides benzene derivatives which are leukotriene antagonists, formulations of those derivatives, intermediates for preparing the derivatives, and a method of using those derivatives for the treatment of conditions characterized by an excessive release of leukotrienes.
    Type: Grant
    Filed: October 16, 1990
    Date of Patent: December 15, 1992
    Assignee: Eli Lilly and Company
    Inventor: D. Mark Gapinski
  • Patent number: 5142069
    Abstract: This invention provides a process and intermediates for preparing 2,2-dimethyl-2,3-dihydrobenzofuran-7-carboxylic acids.
    Type: Grant
    Filed: March 7, 1991
    Date of Patent: August 25, 1992
    Assignee: Eli Lilly and Company
    Inventor: Christopher R. Schmid
  • Patent number: 5141944
    Abstract: This invention provides N-(2-hydroxycyclopentyl)-1-isopropyl-6-methylergoline-8-carboxamides useful for blocking 5HT.sub.2 receptors in mammals having an excess of serotonin centrally or peripherally. The invention also provides methods for treating sexual dysfunction, hypertension, migraine, vasospasm, thrombosis, ischemia, depression, anxiety, sleep disorders and appetite disorders with a compound of the invention.
    Type: Grant
    Filed: June 24, 1991
    Date of Patent: August 25, 1992
    Assignee: Eli Lilly and Company
    Inventors: Marlene L. Cohen, David W. Robertson
  • Patent number: 5136078
    Abstract: This invention provides a process for preparing 3-substituted-3-hydroxypropanenitriles.
    Type: Grant
    Filed: February 26, 1991
    Date of Patent: August 4, 1992
    Assignee: Eli Lilly and Company
    Inventor: David Mitchell
  • Patent number: 5135947
    Abstract: The present invention provides 1-phenyl-3-naphthalenyloxypropanamines which are selective inhibitors of serotonin uptake.
    Type: Grant
    Filed: August 1, 1990
    Date of Patent: August 4, 1992
    Assignee: Eli Lilly and Company
    Inventors: David W. Robertson, David T. Wong, Dennis C. Thompson